Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-02-23 pm EST 5-day change 1st Jan Change
51.66 USD +0.64% Intraday chart for Bristol-Myers Squibb Company +3.61% +0.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bristol-Myers Says European Panel Issues Positive Opinion for Reblozyl to Treat Transfusion-Dependent Anemia MT
Bristol Myers Squibb Says RayzeBio Shareholders Overwhelmingly Accept $4.1 Billion Buyout Offer MT
Bristol Myers: positive CHMP opinion in anemia CF
Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares DJ
Bristol Myers: successful takeover bid for RayzeBio CF
Bristol Myers Gets CHMP Backing for Expanded Reblozyl Use DJ
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial MT
Immunocore Holdings plc Announces Supply Agreement with Bristol Myers Squibb to Provide nivolumab CI
Aurora Cannabis Names Simona King CFO; Completes Share Consolidation MT
Bristol Myers: priority review in colorectal cancer CF
Bristol Myers Gets Priority FDA Review of Expanded Krazati Use DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental New Drug Application for KRAZATI in Combination with Cetuximab for the Treatment of Patients with Previously Treated KRASG12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Pfizer inflammatory bowel disease drug wins EU approval RE
Bristol-Myers Squibb Company Announces Management Changes CI
Bristol Myers: does not approve Tutanota offer CF
Kidney drug developer Aurinia fails to clinch a sale, sources say RE
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday MT
Bristol-Myers Squibb Gets FDA Priority Review for Repotrectinib to Treat Solid Tumors MT
Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use DJ
Bristol Myers: priority review accepted for Augtyro CF
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors CI
VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence CI
Bristol-Myers Squibb, RayzeBio Say Hart-Scott-Rodino Act Waiting Period Expires MT
Bristol Myers: HSR period expires for RayzeBio CF
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer